Reply:
Korosh Khalili, Morris Sherman – 16 November 2011
Protease‐activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells
Virginia Knight, Jorge Tchongue, Dinushka Lourensz, Peter Tipping, William Sievert – 16 November 2011 – Protease‐activated receptor (PAR) 2 is a G‐protein–coupled receptor that is activated after proteolytic cleavage by serine proteases, including mast cell tryptase and activated coagulation factors. PAR‐2 activation augments inflammatory and profibrotic pathways through the induction of genes encoding proinflammatory cytokines and extracellular matrix proteins. Thus, PAR‐2 represents an important interface linking coagulation and inflammation.
To feed or what to feed in cirrhosis?
Richard D. Johnston, Grace E. Dolman, Guruprasad Aithal – 16 November 2011
Histological discrimination between autoimmune hepatitis and drug‐induced liver injury
Keiichi Fujiwara, Osamu Yokosuka – 31 October 2011
The long and the short of interferon‐gamma–inducible protein 10 in hepatitis C virus infection
Mark D. Gorrell, Amany Zekry, Geoffrey W. McCaughan, Andrew Lloyd – 28 October 2011
Boceprevir (Victrelis) for HCV: V is for victory and very complex
Michael Charlton, Michael D. Leise – 28 October 2011
Exhausted or just sleeping: Awakening virus‐specific responses in chronic hepatitis C virus infection
Nicole A.W. Wood, May La Linn, David G. Bowen – 28 October 2011
Opening the door for hepatitis C virus infection in genetically humanized mice
Mirjam B. Zeisel, Daniel Da Costa, Thomas F. Baumert – 28 October 2011
Efficient human fetal liver cell isolation protocol based on vascular perfusion for liver cell–based therapy and case report on cell transplantation
Bruno Gridelli, Giovanni Vizzini, Giada Pietrosi, Angelo Luca, Marco Spada, Salvatore Gruttadauria, Davide Cintorino, Giandomenico Amico, Cinzia Chinnici, Toshio Miki, Eva Schmelzer, Pier Giulio Conaldi, Fabio Triolo, Jörg C. Gerlach – 27 October 2011 – Although hepatic cell transplantation (CT) holds the promise of bridging patients with end‐stage chronic liver failure to whole liver transplantation, suitable cell populations are under debate.
Of mice and men, calcineurin inhibitors and hepatitis C
Alleluiah Rutebemberwa, Hugo R. Rosen – 27 October 2011